sphingotec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies.

sphingotec GmbH was established in 2002 and is located in Hennigsdorf near Berlin, Germany. CEO Dr. Andreas Bergmann was one of the founders of B.R.A.H.M.S. AG. As former Chief Research Officer, he was responsible for the development of the “gold standard” sepsis biomarker Procalcitonin (B.R.A.H.M.S. PCT™).




Dr. rer. nat. Andreas Bergmann
Chief Executive Officer
E-Mail to Andreas Bergmann


Andreas Bergmann has worked in the diagnostic industry for over 25 years. With an outstanding track record, he has spearheaded the discovery, validation and the development of blood biomarkers. Bergmann was one of the founders and managers of B.R.A.H.M.S. AG where the sepsis marker Procalcitonin (PCT®) was developed under his responsibility as Chief Research Officer. B.R.A.H.M.S. AG started as a management buy-out with 180 employees 1994 and grew to approx. 400 employees by 2009. The biomarker Procalcitonin created a new diagnostic standard of care supporting patient management in sepsis. Andreas Bergmann is inventor holding 121 patent rights and also co-author of over 150 peer-reviewed scientific publications.

Bergmann went on to establish sphingotec which is located in Hennigsdorf. He leads the development of diagnostic methods for the prediction, prevention, intervention strategies and early treatment of diseases in the fields of cancer, cardiovascular diseases and acute care. Focusing on plasma biomarkers to indicate the susceptibility of a specific disease, the resulting information can enable monitoring, prevention and intervention strategies. His philosophy is that diagnosis and methods of treatments are to aid in the prevention of diseases rather than having to cure them.

Bergmann studied biochemistry at the Freie Universität Berlin (free university Berlin) and later obtained a PhD in biochemistry at the Technische Universität Berlin (technical university Berlin) in 1987. Before co-founding B.R.A.H.M.S. AG he worked for Henning-Berlin GmbH, Berlin. Dr. Bergmann is also member of the Executive Boards of the “Waltraut Bergmann Stiftung zur Förderung der Krebsforschung”, the Adrenomed AG.


Dr. rer. nat. Ute Kilger
Chief Marketing Officer
E-Mail to Ute Kilger

Ute Kilger has worked in the patent departments of large pharmaceutical companies for over 10 years. Ute Kilger studied chemistry at the University of Merseburg and obtained a PhD in biochemistry at the Freie Universität Berlin. She finished her training as a European patent attorney in the patent department of Boehringer Mannheim GmbH. Afterwards she was patent attorney for Roche Diagnostics GmbH in Mannheim for several years, before she joined the patent department at Schering AG in 2002. During her time at Schering AG, she was involved in comprehensive Due Diligence processes, mergers and acquisitions, and contract negotiations. In 2004 she was appointed Head of Global Patent Business Area Molecular Imaging.

Since August 2009, Ute Kilger is working as a partner at BOEHMERT & BOEHMERT in the areas of biology/chemistry/pharmaceuticals. She frequently lectures on IP protection at the University of Potsdam and at the Charité-Universitätsmedizin Berlin.




Medical Affairs
Dr. rer. nat. Joachim Struck
Vice President Medical Affairs
E-Mail to Joachim Struck


POC Technology
Nam Shin
CEO of Nexus Dx.
E-Mail to Nam Shin


Marketing & Distribution
Deborah Bergmann B.Sc.
Vice President Marketing
E-Mail to Deborah Bergmann



Our company is continually looking for highly motivated team members. If you are interested in joining our innovative team, please contact us at

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help. Privacy Policy | Imprint

Select an option to continue

Your selection was saved!

More information


To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set. Borlabs Cookie already set a necessary cookie.

You can change your cookie setting here anytime: Privacy Policy. Imprint